{"id":"intermediate-dose-enoxaparin","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Bleeding"},{"rate":"0.1-1","effect":"Thrombocytopenia"},{"rate":"1-5","effect":"Injection site hematoma"},{"rate":"1-3","effect":"Elevated transaminases"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enoxaparin is derived from unfractionated heparin and works by potentiating antithrombin III, which inactivates coagulation factors Xa and thrombin (IIa). The intermediate dose formulation provides a balance between anticoagulant efficacy and bleeding risk, making it suitable for thromboprophylaxis and treatment of thromboembolic conditions. It is administered subcutaneously and has predictable pharmacokinetics.","oneSentence":"Intermediate dose enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:31.007Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboprophylaxis in medical and surgical patients"},{"name":"Treatment of acute deep vein thrombosis and pulmonary embolism"},{"name":"Acute coronary syndrome"}]},"trialDetails":[{"nctId":"NCT07312851","phase":"PHASE1","title":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-19","conditions":"Healthy Participants","enrollment":186},{"nctId":"NCT07384598","phase":"NA","title":"Pharmacokinetic Profiles of Subcutaneous Enoxaparin for Thromboprophylaxis in Critically Ill Patients With Renal Failure Treated or Not With Continuous Veno-veinous Hemofiltration.","status":"NOT_YET_RECRUITING","sponsor":"Clinique Saint Pierre Ottignies","startDate":"2026-02-01","conditions":"Thromboprophylaxis, Critical Illness, Intensive Care (ICU)","enrollment":60},{"nctId":"NCT05848713","phase":"PHASE3","title":"AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia","status":"RECRUITING","sponsor":"University of Manitoba","startDate":"2023-10-10","conditions":"Community-acquired Pneumonia","enrollment":4000},{"nctId":"NCT06845423","phase":"PHASE4","title":"Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2025-05-16","conditions":"Venous Thromboembolism (VTE), Post Partum Women","enrollment":2400},{"nctId":"NCT04367831","phase":"PHASE4","title":"Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19","status":"COMPLETED","sponsor":"Columbia University","startDate":"2020-05-02","conditions":"COVID-19, Venous Thromboses, Arterial Thrombosis","enrollment":94},{"nctId":"NCT04427098","phase":"PHASE2","title":"Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients","status":"COMPLETED","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2020-05-22","conditions":"COVID-19","enrollment":301},{"nctId":"NCT06662253","phase":"PHASE2, PHASE3","title":"Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"Alexandre Tran","startDate":"2025-01","conditions":"Venous Thromboembolism (VTE), Trauma Related Injuries","enrollment":150},{"nctId":"NCT04483960","phase":"PHASE3","title":"Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Melbourne","startDate":"2020-07-28","conditions":"SARS-CoV-2 Infection (COVID-19)","enrollment":2200},{"nctId":"NCT06153394","phase":"PHASE3","title":"Prolonged Hypercoagulability Following Major Liver Resection for Malignancy","status":"NOT_YET_RECRUITING","sponsor":"Western University, Canada","startDate":"2024-06-01","conditions":"Hepatic Disease, Surgery-Complications, Hypercoagulability","enrollment":50},{"nctId":"NCT02604238","phase":"PHASE3","title":"Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism","status":"WITHDRAWN","sponsor":"Azienda U.S.L. 1 di Massa e Carrara","startDate":"2016-03","conditions":"Pulmonary Embolism","enrollment":""},{"nctId":"NCT04406389","phase":"PHASE4","title":"Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2020-10-13","conditions":"COVID-19","enrollment":14},{"nctId":"NCT04646655","phase":"PHASE3","title":"Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19","status":"COMPLETED","sponsor":"ASST Fatebenefratelli Sacco","startDate":"2020-07-27","conditions":"Covid19, Thrombosis","enrollment":142},{"nctId":"NCT05901337","phase":"NA","title":"Cupping Therapy on Immune System in Post Covid -19","status":"COMPLETED","sponsor":"Cairo University","startDate":"2022-03-07","conditions":"Covid-19 Patients","enrollment":76},{"nctId":"NCT04360824","phase":"PHASE4","title":"Covid-19 Associated Coagulopathy","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2020-05-06","conditions":"COVID 19 Associated Coagulopathy","enrollment":176},{"nctId":"NCT01828697","phase":"PHASE4","title":"Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2013-04-24","conditions":"Deep Venous Thrombosis, Pulmonary Embolism","enrollment":1110},{"nctId":"NCT05304702","phase":"","title":"Lung Injury (Pulmonary Edema) in COVID-19: Treatment With Furosemide and Negative Fluid Balance (NEGBAL)","status":"COMPLETED","sponsor":"Clinica Colon","startDate":"2021-11-28","conditions":"COVID-19","enrollment":120},{"nctId":"NCT04374539","phase":"PHASE2","title":"Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial","status":"TERMINATED","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2020-04-29","conditions":"Coronavirus","enrollment":36},{"nctId":"NCT04377997","phase":"PHASE2","title":"Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2020-05-15","conditions":"Cardiovascular Diseases, COVID-19","enrollment":300},{"nctId":"NCT05172115","phase":"PHASE3","title":"Catheter-Directed Thrombolysis Versus Anticoagulation Monotherapy in Intermediate-High Risk PE","status":"TERMINATED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2018-12-22","conditions":"Pulmonary Embolism, Pulmonary Thromboembolisms, Embolism, Pulmonary","enrollment":94},{"nctId":"NCT04401293","phase":"PHASE3","title":"Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2020-04-26","conditions":"Sars-CoV2, COVID","enrollment":257},{"nctId":"NCT04486508","phase":"PHASE3","title":"Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19","status":"COMPLETED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2020-07-30","conditions":"Covid19","enrollment":600},{"nctId":"NCT04485429","phase":"PHASE3","title":"Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia","status":"WITHDRAWN","sponsor":"D'Or Institute for Research and Education","startDate":"2020-07-20","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04394377","phase":"PHASE4","title":"Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial","status":"COMPLETED","sponsor":"Brazilian Clinical Research Institute","startDate":"2020-06-21","conditions":"Coronavirus Infection","enrollment":615},{"nctId":"NCT04520620","phase":"PHASE4","title":"Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention","status":"WITHDRAWN","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2020-05-02","conditions":"Sars-CoV2","enrollment":""},{"nctId":"NCT01662908","phase":"PHASE2","title":"A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2012-08","conditions":"Deep Vein Thrombosis, Venous Thrombosis","enrollment":85},{"nctId":"NCT01589393","phase":"NA","title":"OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage (OPTTTICH Feasibility Study)","status":"COMPLETED","sponsor":"McMaster University","startDate":"2010-09","conditions":"Traumatic Intracranial Haemorrhage","enrollment":52},{"nctId":"NCT03299296","phase":"PHASE3","title":"Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin","status":"UNKNOWN","sponsor":"Ahmed AbdelMoneim Hassan Ali","startDate":"2017-01-01","conditions":"Thromboses, Deep Vein, Surgery--Complications","enrollment":100},{"nctId":"NCT02696330","phase":"PHASE4","title":"Comparison Between Effect of Enoxaparin and Clopidogrel on Improving Pregnancy Rate in ICSI","status":"UNKNOWN","sponsor":"Ain Shams Maternity Hospital","startDate":"2015-09","conditions":"Female , Infertility","enrollment":150},{"nctId":"NCT01356992","phase":"PHASE3","title":"Patients With High-risk Acute Coronary Syndrome Without ST-segment Elevation","status":"TERMINATED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2012-07","conditions":"Non ST Segment Elevation Myocardial Infarction, Unstable Angina","enrollment":62},{"nctId":"NCT02260908","phase":"NA","title":"OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage - Pilot Study","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2014-10","conditions":"Traumatic Intracranial Haemorrhage","enrollment":300},{"nctId":"NCT01164046","phase":"PHASE3","title":"Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism","status":"TERMINATED","sponsor":"University Medical Center Groningen","startDate":"2010-08","conditions":"Venous Thromboembolism, Neoplasms","enrollment":56},{"nctId":"NCT02240927","phase":"NA","title":"Anticoagulation Regimens in Pregnant Patients With Prosthetic Heart Valves","status":"UNKNOWN","sponsor":"Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital","startDate":"2010-01","conditions":"Pregnancy, Heart; Complications, Valve, Prosthesis","enrollment":40},{"nctId":"NCT00113932","phase":"PHASE2","title":"UARK 2003-41: A Study of High-Dose Density Therapy in Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2003-12","conditions":"Multiple Myeloma","enrollment":140},{"nctId":"NCT00412802","phase":"PHASE4","title":"Adaptation Dose of Enoxaparin in Moderate Renal Failure Patients With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"French Cardiology Society","startDate":"2006-12","conditions":"Acute Coronary Syndrome, Renal Failure","enrollment":67}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["enoxaparin","Clexane"],"phase":"marketed","status":"active","brandName":"Intermediate dose enoxaparin","genericName":"Intermediate dose enoxaparin","companyName":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","companyId":"academisch-medisch-centrum-universiteit-van-amsterdam-amc-uva","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intermediate dose enoxaparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factors Xa and IIa. Used for Thromboprophylaxis in medical and surgical patients, Treatment of acute deep vein thrombosis and pulmonary embolism, Acute coronary syndrome.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}